08 September 2025
Altacor, the UK-based ophthalmology company behind the Clinitas dry eye products, has been acquired by Fidia Farmaceutici.
The acquisition marks the entry of Fidia into the UK market, and the company suggests this will enable it to enhance Altacor’s portfolio, as well as introducing its own products to the UK.
Fidia Farmaceutici manufactures products primarily based on hyaluronic acid across joint, skin, eye, specialty, and health and wellness care.
Products from the company include Fidia Hyaluronic Acid (FHA 1.0) designed to address different forms of dry eye disease, as well as diagnostic stains for ocular surface diseases, supplements, and platforms supporting cataract and corneal crosslinking surgeries.
The acquisition is part of a wider €150 million investment plan for 2025-2026 and is the latest in a series of expansion initiatives from Fidia.
Carlo Pizzocaro, president and CEO of Fidia Farmaceutici, said: “The acquisition of Altacor represents another milestone in our international growth journey.”
“We are increasingly focusing our investments on high-potential markets, such as the UK, to strengthen our global presence and expand into new therapeutic areas,” he added.
In 2024, Fidia reported revenues exceeding €500 million, up 10.1% year-on-year, with double-digit growth across key markets in Italy, Europe, the Middle East and North Africa, and the US.
Comments (0)
You must be logged in to join the discussion. Log in